EyePoint (EYPT) Intangibles (2011 - 2022)
EyePoint (EYPT) posted Intangibles of $47.6 million for Q4 2022, down 30.3% sequentially from $68.3 million in Q3 2022, and down 30.3% YoY from $68.3 million in Q4 2021.
EyePoint (EYPT) Intangibles (2011 - 2022) Analysis & Trends
EyePoint has reported Intangibles for 12 years, with the latest figure at $47.6 million in Q4 2022.
- Quarterly Intangibles fell 30.3% year-over-year to $47.6 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $47.6 million (down 30.3% YoY) and the FY2022 annual result came in at $47.6 million, down 30.3% from the prior year.
- Intangibles eased to $47.6 million in Q4 2022 per EYPT's latest filing, from $68.3 million in the prior quarter.
- Over five years, Intangibles peaked at $68.3 million in Q2 2018 and troughed at $21.5 million in Q2 2022.
- A 5-year average of $58.7 million and a median of $68.3 million in 2018 frame the typical range for Intangibles.
- The sharpest annual moves came in 2018 and 2022: Intangibles jumped 5820.93% in 2018, then slumped 68.5% in 2022.
- Over 5 years, Intangibles stood at $68.3 million in 2018, then changed by 0.0% to $68.3 million in 2019, then changed by 0.0% to $68.3 million in 2020, then changed by 0.0% to $68.3 million in 2021, then slumped by 30.3% to $47.6 million in 2022.
- According to Business Quant data, Intangibles over the past three periods registered $47.6 million, $68.3 million, and $21.5 million for Q4 2022, Q3 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 47.62 Mn |
| Sep 30, 2022 | 68.32 Mn |
| Jun 30, 2022 | 21.52 Mn |
| Mar 31, 2022 | 22.13 Mn |
| Dec 31, 2021 | 68.32 Mn |
| Sep 30, 2021 | 68.32 Mn |
| Jun 30, 2021 | 68.32 Mn |
| Mar 31, 2021 | 68.32 Mn |
| Dec 31, 2020 | 68.32 Mn |
| Sep 30, 2020 | 25.82 Mn |
| Jun 30, 2020 | 68.32 Mn |
| Mar 31, 2020 | 68.32 Mn |
| Dec 31, 2019 | 68.32 Mn |
| Sep 30, 2019 | 68.32 Mn |
| Jun 30, 2019 | 68.32 Mn |
| Mar 31, 2019 | 68.32 Mn |
| Dec 31, 2018 | 68.32 Mn |
| Sep 30, 2018 | 68.32 Mn |
| Jun 30, 2018 | 68.32 Mn |
| Mar 31, 2018 | 31.97 Mn |